Latest news
AstraZeneca’s potential $1.5B insitro deal puts AI on the hardest question in cardiometabolic R&D
AstraZeneca has partnered with AI therapeutics company insitro to discover new targets and medicines for MASH and cardiomyopathies, paying $40 million upfront with up to $1.46 billion tied to future development and commercial milestones.
Depression Is Not One Score, and TMS Proves It
Hepatitis A Exposed A Travel Gap.
Can Home-Based Cardiac Rehab Close the Participation Gap?
From Patients to Customers: GLP-1 Marketing Is Rewriting Obesity Care
IPM Brief – Special edition | From UNGA to Dublin | Turning innovation into access
Breast Cancer Radiation De-Escalation Has an Adherence Problem
Clearing Amyloid Is Not the Same as Saving Cognition
Europe’s Infection Gap Starts At The Clinic Door
Cardiac Amyloidosis Has a Diagnostic Grey Zone. A New PET Tracer Could Help Close It
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.